Search Results - "Jett, John E."

Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia by Walling, David, Marder, Stephen R, Kane, John, Fleischhacker, W Wolfgang, Keefe, Richard S E, Hosford, David A, Dvergsten, Chris, Segreti, Anthony C, Beaver, Jessica S, Toler, Steven M, Jett, John E, Dunbar, Geoffrey C

“…This trial was conducted to test the effects of an alpha7 nicotinic receptor full agonist, TC-5619, on negative and cognitive symptoms in subjects with…”
Get full text

Src binds cortactin through an SH2 domain cystine-mediated linkage by Evans, Jason V, Ammer, Amanda G, Jett, John E, Bolcato, Chris A, Breaux, Jason C, Martin, Karen H, Culp, Mark V, Gannett, Peter M, Weed, Scott A

“…Tyrosine-kinase-based signal transduction mediated by modular protein domains is critical for cellular function. The Src homology (SH)2 domain is an important…”
Get full text

A Phase 1b, Randomized, Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis by Piscitelli, Stephen C., Pavel, Ana B., McHale, Kimberly, Jett, John E., Collins, Jon, Gillmor, Dawn, Tabolt, Glenn, Li, Randall, Song, Teresa, Zhang, Ning, Tallman, Anna M., Guttman-Yassky, Emma

Get full text

Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics by Jett, John E., McLaughlin, Michael, Lee, Mark S., Parish, Lawrence Charles, DuBois, Janet, Raoof, Tooraj Joseph, Tabolt, Glenn, Wilson, Timothy, Somerville, Matthew C., DellaMaestra, Wayne, Piscitelli, Stephen C.

“…Background Tapinarof is a novel topical therapeutic aryl hydrocarbon receptor modulating agent in development for the treatment of psoriasis and atopic…”
Get full text

Measurement of Electron Transfer through Cytochrome P450 Protein on Nanopillars and the Effect of Bound Substrates by Jett, John E, Lederman, David, Wollenberg, Lance A, Li, Debin, Flora, Darcy R, Bostick, Christopher D, Tracy, Timothy S, Gannett, Peter M

“…Electron transfer in cytochrome P450 enzymes is a fundamental process for activity. It is difficult to measure electron transfer in these enzymes because under…”
Get full text

Identification and pharmacological characterization of 3,6-diazabicyclo[3.1.1]heptane-3-carboxamides as novel ligands for the α4β2 and α6/α3β2β3 nicotinic acetylcholine receptors (nAChRs) by Strachan, Jon-Paul, Kombo, David C., Mazurov, Anatoly, Heemstra, Ronald, Bhatti, Balwinder S., Akireddy, Rao, Murthy, Srinivasa, Miao, Lan, Jett, John E., Speake, Jason, Bencherif, Merouane

“…We have synthesized a novel series of compounds, 3,6-diazabicyclo[3.1.1]heptane-3-carboxamides, targeting both the α4β2 and α6/α3β2β3 nAChRs. Members of the…”
Get full text

Selective filling of nanowells in nanowell arrays fabricated using polystyrene nanosphere lithography with cytochrome P450 enzymes by Wollenberg, Lance A, Jett, John E, Wu, Yueting, Flora, Darcy R, Wu, Nianqiang, Tracy, Timothy S, Gannett, Peter M

“…This work describes an original and simple technique for protein immobilization into nanowells, fabricated using nanopatterned array fabrication methods, while…”
Get more information

41626 Tapinarof Cream 1% Once Daily for Plaque Psoriasis in Two Pivotal Phase 3 Trials: Minimal Systemic Exposure is Consistent With Adverse Event Profile by Gold, Linda Stein, Lebwohl, Mark G., Brown, Philip M., Rubenstein, David S., Tabolt, Glenn, Jett, John E., Piscitelli, Stephen C.

Get full text

301 Tapinarof cream 1% once daily for the treatment of extensive atopic dermatitis in adolescents and children: 4-week maximal use trial by Paller, Amy, Hebert, Adelaide A, Jett, John E, Brown, Philip M, Rubenstein, David S, Piscitelli, Stephen C

“…There is a need for efficacious non-steroidal topical therapies for atopic dermatitis (AD) without restrictions relating to duration, the extent of use and…”
Get full text

406 Tapinarof cream 1% once daily for the treatment of extensive atopic dermatitis in adolescents and children: outcomes from the 4-week maximal usage trial by Paller, Amy, Jett, John E, Hebert, Adelaide, Brown, Philip M, Butners, Victoria, Fitzgerald, Nancy , Delgado, Marta, Gonzalez, Mercedes E, Piscitelli, Stephen C

“…Tapinarof is a first-in-class, nonsteroidal, topical, aryl hydrocarbon receptor agonist approved by the Food and Drug Administration for the treatment of…”
Get full text

Tapinarof Cream 1% Once Daily for the Treatment of Extensive Atopic Dermatitis in Adolescents and Children: 4-Week Maximal-Use Trial by Paller, Amy, Hebert, Adelaide A., Jett, John E, Brown, Philip M., Rubenstein, David S., Piscitelli, Stephen

Get full text

Exposure–Response Analysis Demonstrates Response to Tapinarof is Driven by Local Effects at Sites of Application by Del Rosso, James, Guenthner, Scott, Hong, Chih-ho, Jett, John E, Brown, Philip M., Rubenstein, David S., Piscitelli, Stephen

Get full text

Tapinarof Cream 1% Once Daily for the Treatment of Extensive Atopic Dermatitis in Adolescents and Children: 4-Week Maximal-Use Trial by Paller, Amy, Hebert, Adelaide A, Jett, John E, Brown, Philip M, Rubenstein, David S, Piscitelli, Stephen C

Get full text

Exposure–Response Analysis Demonstrates Response to Tapinarof is Driven by Local Effects at Sites of Application by Del Rosso, James, Guenthner, Scott, Hong, Chih-ho, Jett, John E, Brown, Philip M, Rubenstein, David S, Piscitelli, Stephen C

Get full text